By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...